SandboxAlonso: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 1: Line 1:
{{Sotalol}}
{{drugbox |
| IUPAC_name = ''N''-[4-(1-hydroxy-2-isopropylamino-<br>ethyl)-phenyl]-methanesulfonamide
| image = Sotalol.png
| CAS_number = 3930-20-9
| ATC_prefix=C07
| ATC_suffix=AA07
| PubChem=5253
| DrugBank=
| C=12 | H=20 | N=2 | O=3 | S=1
| molecular_weight =  272.3624 g/mol
| bioavailability = >95%
| metabolism = Not metabolised
| elimination_half-life = 12 hours
| excretion = [[Kidney|Renal]] <br> [[Mammary gland|Lactic]] (In lactating females)
| pregnancy_AU =
| pregnancy_US = B
| pregnancy_category =
| legal_status = Rx-only
| routes_of_administration = oral
}}
__NOTOC__
__NOTOC__
{{CMG}}
{{Acebutolol}}
{{CMG}}; {{AE}} {{SS}}


'''''For patient information about Sotalol, click [[Sotalol (patient information)|here]].'''''
'''''For patient information about Acebutolol, click [[Acebutolol (patient information)|here]].'''''


{{SB}} BETAPACE, SOTALOL HYDROCHLORIDE
{{SB}} SECTRAL<sup>®</sup>


==Overview==
==Overview==


'''Sotalol''' (trade names '''Betapace''' and '''Betapace AF''', [[Berlex Laboratories]]) is a [[medication|drug]] used in individuals with rhythm disturbances ([[cardiac arrhythmia]]s) of the [[heart]], and to treat [[hypertension]] in some individuals.
Sectral (acebutolol HCl) is a selective, hydrophilic beta-adrenoreceptor blocking agent with mild intrinsic sympathomimetic activity for use in treating patients with hypertension and ventricular arrhythmias


==Category==
==Category==


Beta Blockers
Beta blockers


==FDA Package Insert==
==FDA Package Insert==


====BETAPACE (sotalol hydrochloride) tablet====
====SECTRAL (acebutolol hydrochloride) capsule====


'''  [[Sotalol tablet indications and usage|Indications and Usage]]'''
'''  [[Acebutolol indications and usage|Indications and Usage]]'''
'''| [[Sotalol tablet dosage and administration|Dosage and Administration]]'''
'''| [[Acebutolol dosage and administration|Dosage and Administration]]'''
'''| [[Sotalol tablet contraindications|Contraindications]]'''
'''| [[Acebutolol dosage forms and strengths|Dosage Forms and Strengths]]'''
'''| [[Sotalol tablet warnings and precautions|Warnings and Precautions]]'''
'''| [[Acebutolol contraindications|Contraindications]]'''
'''| [[Sotalol tablet adverse reactions|Adverse Reactions]]'''
'''| [[Acebutolol warnings and precautions|Warnings and Precautions]]'''
'''| [[Sotalol tablet drug interactions|Drug Interactions]]'''
'''| [[Acebutolol adverse reactions|Adverse Reactions]]'''
'''| [[Sotalol tablet use in specific populations|Use in Specific Populations]]'''
'''| [[Acebutolol drug interactions|Drug Interactions]]'''
'''| [[Sotalol tablet overdosage|Overdosage]]'''
'''| [[Acebutolol use in specific populations|Use in Specific Populations]]'''
'''| [[Sotalol tablet description|Description]]'''
'''| [[Acebutolol overdosage|Overdosage]]'''
'''| [[Sotalol tablet clinical pharmacology|Clinical Pharmacology]]'''
'''| [[Acebutolol description|Description]]'''
'''| [[Sotalol tablet clinical studies|Clinical Studies]]'''
'''| [[Acebutolol clinical pharmacology|Clinical Pharmacology]]'''
'''| [[Sotalol tablet how supplied storage and handling|How Supplied/Storage and Handling]]'''
'''| [[Acebutolol nonclinical toxicology|Nonclinical Toxicology]]'''
'''| [[Sotalol tablet labels and packages|Labels and Packages]]'''
'''| [[Acebutolol how supplied storage and handling|How Supplied/Storage and Handling]]'''
'''| [[Acebutolol patient counseling information|Patient Counseling Information]]'''
'''| [[Acebutolol labels and packages|Labels and Packages]]'''


{|
==Mechanism of Action==
| [[File:Sotabb1.png|thumb|800px]]
|}


====SOTALOL HYDROCHLORIDE injection====
The mechanism of action has not been definitively established. Possible factors that may be involved include: (1) decreased heart rate, (2) decreased myocardial contractility, (3) diminution of tonic sympathetic outflow to the periphery from cerebral vasomotor centers, (4) suppression of renin activity and (5) vasodilation and decreased peripheral vascular resistance.
 
'''  [[Sotalol injection indications and usage|Indications and Usage]]'''
'''| [[Sotalol injection dosage and administration|Dosage and Administration]]'''
'''| [[Sotalol injection dosage forms and strengths|Dosage Forms and Strengths]]'''
'''| [[Sotalol injection contraindications|Contraindications]]'''
'''| [[Sotalol injection warnings and precautions|Warnings and Precautions]]'''
'''| [[Sotalol injection adverse reactions|Adverse Reactions]]'''
'''| [[Sotalol injection drug interactions|Drug Interactions]]'''
'''| [[Sotalol injection use in specific populations|Use in Specific Populations]]'''
'''| [[Sotalol injection overdosage|Overdosage]]'''
'''| [[Sotalol injection description|Description]]'''
'''| [[Sotalol injection clinical pharmacology|Clinical Pharmacology]]'''
'''| [[Sotalol injection nonclinical toxicology|Nonclinical Toxicology]]'''
'''| [[Sotalol injection clinical studies|Clinical Studies]]'''
'''| [[Sotalol injection how supplied storage and handling|How Supplied/Storage and Handling]]'''
'''| [[Sotalol injection patient counseling information|Patient Counseling Information]]'''
'''| [[Sotalol injection labels and packages|Labels and Packages]]'''
 
{|
| [[File:Sotabb2.png|thumb|800px]]
|}
 
==Pharmacology==
 
It falls into the class III [[antiarrhythmic agents]] because it inhibits the inward [[potassium]] [[ion channel]]s in the heart.  It is also a [[beta blocker]] because of its primary action on the &beta;-[[adrenergic receptor]]s in the heart.
 
By blocking the [[potassium channel]]s, sotalol prolongs [[repolarization]], therefore lengthening the [[QT interval]] and decreasing [[automaticity]].
 
It also slows [[AV node|atrioventricular (AV) nodal]] conduction (beta-blocking effect).
 
Sotalol is a [[racemic]] mix of D and L [[enantiomers]].  The ''L''-isomer is a [[beta blocker]].
 
Sotalol is not selected for its beta-blocking ability, but rather for its Class III (potassium blocking) properties.
 
==Indications==
 
Sotalol is used to treat [[ventricular tachycardia]]s as well as [[atrial fibrillation]]. Betapace AF is specifically labeled for [[atrial fibrillation]].
 
Some evidence suggests that sotalol should be avoided in the setting of decreased [[ejection fraction]] due to [[myocardial infarction|heart attack]].


==References==
==References==


{{Reflist|2}}
{{Reflist|2}}
==See Also==
*[[Antiarrhythmic agents]]
*[[Beta blocker]]


{{beta blockers}}
{{beta blockers}}


[[Category:Antiarrhythmic agents]]
[[Category:Beta blockers]]
[[Category:Beta blockers]]
[[Category:Cardiovascular Drugs]]
[[Category:Cardiovascular Drugs]]
[[Category:Drugs]]
[[Category:Drugs]]

Revision as of 17:05, 9 July 2014

Acebutolol
SECTRAL® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

For patient information about Acebutolol, click here.

Synonyms / Brand Names: SECTRAL®

Overview

Sectral (acebutolol HCl) is a selective, hydrophilic beta-adrenoreceptor blocking agent with mild intrinsic sympathomimetic activity for use in treating patients with hypertension and ventricular arrhythmias

Category

Beta blockers

FDA Package Insert

SECTRAL (acebutolol hydrochloride) capsule

Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages

Mechanism of Action

The mechanism of action has not been definitively established. Possible factors that may be involved include: (1) decreased heart rate, (2) decreased myocardial contractility, (3) diminution of tonic sympathetic outflow to the periphery from cerebral vasomotor centers, (4) suppression of renin activity and (5) vasodilation and decreased peripheral vascular resistance.

References

Retrieved from "https://www.wikidoc.org/index.php?title=SandboxAlonso&oldid=990910"